This site is intended for health professionals only

Thursday 22 August 2019
Share |

Latest News

Dupilumab reaches primary and secondary endpoints in paediatric trial

Thursday 8th August 2019
A pivotal Phase III trial evaluating Dupixent® (dupilumab) in severe atopic dermatitis in children has met its primary and secondary endpoints. 
The topline data show that for children with severe atopic dermatitis (covering nearly 60% of their skin surface on average), adding Dupixent to standard-of-care topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching and health-...
Thu, 8 Aug 2019
The research, published in Science Advances, involved an international collaboration of the world's leading coeliac disease experts
Thu, 8 Aug 2019
It is hoped that the new guidance will help prescribers better understand which patients' health could be put at risk by using an organiser and also help patients and their carers know what they can ask for to help with taking medicines as prescribed.
Wed, 7 Aug 2019
Dupixent is now the first biologic medicine approved in the EU to treat these patients.
Wed, 7 Aug 2019
Neratinib, which is taken as 6 x 40 mg tablets daily for one year, represents a further adjuvant treatment option in the early breast cancer treatment pathway
Tue, 6 Aug 2019
Parkinson’s UK have partnered with the University of Sheffield to develop a treatment that could protect brain cells affected by Parkinson’s
Fri, 2 Aug 2019
The University of Edinburgh study shows that Crohn's disease affects 284 people out of every 100,000 in Scotland's capital
Fri, 2 Aug 2019
People with Lynch syndrome have an increased lifetime risk – estimated to be four out of five people – of developing colorectal cancer